In a further study, The single nucleotide polymorphisms of HMGB1 were identified to be correlated with adverse clinical outcomes in prostate cancer, including higher D’Amico classification, higher pathologic Gleason subgroups, and higher pathologic stage (92). This evidence concerns the gene HMGB1 and prostate carcinoma.